Η κετογονική δίαιτα (χαμηλοί υδατάνθρακες, περιορισμένη πρωτεΐνη και υψηλή περιεκτικότητα σε λιπαρά) δείχνει βελτιωμένη αποτελεσματικότητα μιας νέας κατηγορίας αντικαρκινικών φαρμάκων στη θεραπεία του καρκίνου
ΚΑΡΚΙΝΟΣ Η θεραπεία βρίσκεται στην πρώτη γραμμή της ιατρικής και ερευνητικής κοινότητας παγκοσμίως. 100 τοις εκατό επιτυχημένη θεραπεία για Καρκίνος is still not available and majority of research has been focusing on making Καρκίνος cells in the body susceptible to chemotherapy or radiation therapy or targeted medicines. An emerging new class of Καρκίνος drugs have been actively researched upon in the recent years. These drugs target a specific molecular pathway which become faulty in many types of Καρκίνος – a cell signalling pathway called phosphatidylinositol-3 kinase (PI3K), which is activated by insulin. PI3K, a family of enzymes plays a key role in many internal cellular functions that are involved in cancer. Genetic mutations in PI3K enzyme is present in most καρκινώδης tumours. It is this frequency of mutations which makes PI3K an appealing candidate to make anti-Καρκίνος drugs. Inhibiting pathway of this enzyme is seen as a potential way to attack Καρκίνος. For achieving this goal, more than 50 drugs have been designed and developed so far which have already been through clinical trials for testing for efficacy. Unfortunately, these clinical trials haven’t been much of a success, owing to questionable efficacy of these drugs and also their high toxicity. Taking such drugs which are going to inhibit the pathway leads to a drop in insulin in the body which only increases blood sugar level causing problems like hyperglycemia or abnormally high levels of blood sugar. Patients have to stop taking this drug because pancreas is eventually unable to make up for this loss by producing more insulin after doing it for some time.
Συνδυασμός κετο δίαιτας με θεραπεία καρκίνου
Μια νέα μελέτη που δημοσιεύθηκε στο Φύση έχει δείξει ότι η κετογονική ή κετο δίαιτα is efficient for eliminating some of the side effects of new generation Καρκίνος φάρμακα and can be very beneficial in Καρκίνος therapy. The ketogenic diet constitutes of meat, eggs and avocados as staple food items. The idea of this diet is to eat very few carbohydrates – which are quickly broken down to blood sugar – and also moderate protein – which can also get converted into blood sugar. This diet makes our body produce small fuel molecules called ‘ketones’ (hence the name ketogenic) and they are produced in the body in the liver exclusively from only fat. Ketones are like an alternative fuel for the body whenever sugar (glucose) is in limited supply, including the brain. Therefore, the body basically switches its fuel supply and ‘runs’ entirely on fat as no carbohydrates and limited protein is being produced. This may not be the ideal scenario but is efficient to lose weight and maintain yourself. The keto diet has been used since many decades to control insulin levels in the body.
Following a ketogenic (or ‘keto’) diet can have useful effects during Καρκίνος therapeutic treatment and side effects of new class of Καρκίνος drugs can be avoided. Researchers from Cornell University first examined the effect of PI3K-inhibting drug called buparlisib in mice suffering from pancreatic Καρκίνος. When the insulin levels increased as a side effect to using this drug, PI3K pathway reactivated and Καρκίνος treatment reverses, rendering the drug as ineffective. To be able to control this effect of elevation of insulin which was happening whenever the drug was taken, a follow up drug treatment needed to be done. They tried various options like blood sugar or insulin controlling drugs etc and tested on mice, however, no effect was seen. Interestingly they observed that mice who were on keto diet performed better in maintaining blood sugar and insulin check while simultaneously inhibiting tumour growth which is the desired scenario. This was possible because while being on a keto diet, there was reduced glycogen storage so no extra glucose was released when PI3K pathway was inhibited. Therefore, once a patient is able to control his/her sugar and insulin, Καρκίνος drugs work much better and more efficiently in controlling the growth of tumours.
Keto diet does not have any role on its own in inhibiting or treating the Καρκίνος and if taken alone without any enzyme inhibitors, Καρκίνος still progresses at an expected pace. The diet itself could be harmful if taken on your own for too long. Therefore, keto diet needs to be ideally combined with the actual course of Καρκίνος treatment. As an outcome of this study, during human clinical trials for PI3K inhibitor drugs, diet of the patients’ needs to be carefully managed. Researchers would like to assess if combining approved PI3K inhibitor drugs and keto diet (specially prepared by διατροφολόγοι) can show a safe, efficient and improved outcome for people suffering from different types of Καρκίνος.
***
{Μπορείτε να διαβάσετε την αρχική ερευνητική εργασία κάνοντας κλικ στον σύνδεσμο DOI που δίνεται παρακάτω στη λίστα των αναφερόμενων πηγών}
Πηγές)
Hopkins BD et al 2018. Η καταστολή της ανάδρασης ινσουλίνης ενισχύει την αποτελεσματικότητα των αναστολέων PI3K. Φύση.
https://doi.org/10.1038/s41586-018-0343-4
***
